Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression
Open Access
- 18 November 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 9 (1), 1-11
- https://doi.org/10.1038/s41598-019-53529-z
Abstract
Dopamine and cAMP regulated phosphoprotein 32 kDa (DARPP-32) also known as phosphoprotein phosphatase-1 regulatory subunit 1B and encoded by the PPP1R1B gene is an inhibitor of protein phosphatase-1 and protein kinase A. DARPP-32 is expressed in a wide range of epithelial cells and some solid tumours; however, its role in breast cancer is only partially defined. DARPP-32 expression was determined using immunohistochemistry in two independent cohorts of early stage invasive breast cancer patients (discovery n = 1352; validation n = 1655), and 112 HER2 positive breast cancer patients treated with trastuzumab and adjuvant chemotherapy. PPP1R1B mRNA expression was assessed in the METABRIC cohort (n = 1980), using artificial neural network analysis to identify associated genes. In the discovery cohort, low nuclear expression of DARPP-32 was significantly associated with shorter survival (P = 0.041), which was independent of other prognostic variables (P = 0.019). In the validation cohort, low cytoplasmic and nuclear expression was significantly associated with shorter survival (both P = 0.002), with cytoplasmic expression independent of other prognostic variables (P = 0.023). Stronger associations with survival in oestrogen receptor (ER) positive disease were observed. In patients treated with trastuzumab, low nuclear expression was significantly associated with adverse progression-free survival (P = 0.031). In the METABRIC cohort, low PPP1R1B expression was associated with shortened survival of ER positive patients. Expression of CDC42 and GRB7, amongst others, were associated with PPP1R1B expression. This data suggests a role for DARPP-32 as a prognostic marker with clinical utility in breast cancer.Keywords
Funding Information
- University of Nottingham (Research Vision Award)
This publication has 41 references indexed in Scilit:
- DARPP32, STAT5 and STAT3 mRNA Expression Ratios in Glioblastomas are Associated with Patient OutcomePathology and Oncology Research, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancerMolecular Cancer, 2010
- Wnt-5a-induced Phosphorylation of DARPP-32 Inhibits Breast Cancer Cell Migration in a CREB-dependent MannerJournal of Biological Chemistry, 2009
- Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin ResistancePLOS ONE, 2009
- Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancersBreast Cancer Research and Treatment, 2009
- Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer CellsClinical Cancer Research, 2008
- Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1Experimental Cell Research, 2006
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Overexpression of the 32‐kilodalton dopamine and cyclic adenosine 3′,5′‐monophosphate‐regulated phosphoprotein in common adenocarcinomasCancer, 2003